ATTAIN-CN

Not yet recruitingPhase 3

A Study of Orforglipron (LY3502970) in Chinese Participants With Obesity or Overweight and Weight-Related Health Problems

A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once- Daily Oral Orforglipron Compared With Placebo in Chinese Adult Participants With Obesity or Overweight With Weight-Related Comorbidities

Lead sponsor

Eli Lilly and Company

Asset

Orforglipron

Oral · GLP-1 agonist

Listed sites

Recruiting sites

Estimated enrollment

192

Study population

Obesity / overweight

Eligibility highlights

•BMI ≥28

Primary endpoint

•Mean Percent Change From Baseline in Body Weight

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT07790861

Org study ID27942

Secondary IDJ2A-GH-GZVCEli Lilly and Company

Timeline

Milestones

Study first posted2026-08-27actual

Last update posted2026-10-13actual

Study start2026-12estimated (month precision)

Primary completion2028-03estimated (month precision)

Study completion2028-03estimated (month precision)

Assets

Investigational agents

Orforglipron

Who this study enrolls

Obesity / overweight

Who can enroll

Minimum age18 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•Have body mass index (BMI) ≥28.0 kilograms per square meter (kg/m2) and <30 kg/m2 or ≥24.0 kg/m2 and <28 kg/m2, and at least 1 of the following weight-related comorbidities at screening:

-hypertension

-dyslipidemia

-obstructive sleep apnea

-Fatty liver

-cardiovascular disease

•Have a history of at least 1 self-reported unsuccessful dietary effort to lose body weight

Exclusion criteria

•Have type 1 diabetes (T1D), type 2 diabetes (T2D), or any other types of diabetes, history of ketoacidosis, or hyperosmolar state/coma

•Have a self-reported change in body weight >5 kg within 90 days prior to screening

•Had chronic or acute pancreatitis any time prior to screening

•Have family (first-degree relative) or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2) syndrome

Endpoints (11)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Cardiometabolic biomarkers

Weight & body composition

Glycemic / diabetes

Patient-reported / QoL

Weight & body composition

3 endpoints

Primary/protocol endpoint

Mean Percent Change From Baseline in Body Weight

Time frame:Baseline, Week 48

percent change from baseline, improvement

Secondary/protocol endpoint

Mean Change from Baseline in Waist Circumference

Time frame:Baseline, Week 48

change from baseline, improvement

Secondary/protocol endpoint

Mean Change from Baseline in Body Mass Index (BMI)

Time frame:Baseline, Week 48

change from baseline, improvement

Glycemic / diabetes

3 endpoints

Secondary/protocol endpoint

Mean Change from Baseline in Hemoglobin A1c (HbA1c)

Time frame:Baseline, Week 48

change from baseline, improvement

Secondary/protocol endpoint

Mean Change from Baseline in Fasting Glucose

Time frame:Baseline, Week 48

change from baseline, improvement

Secondary/protocol endpoint

Mean Percent Change from Baseline in Fasting Insulin

Time frame:Baseline, Week 48

percent change from baseline, improvement

Cardiometabolic biomarkers

4 endpoints

Secondary/protocol endpoint

Mean Change from Baseline in Systolic Blood Pressure (SBP)

Time frame:Baseline, Week 48

change from baseline, improvement

Secondary/protocol endpoint

Mean Change from Baseline in Diastolic Blood Pressure (DBP)

Time frame:Baseline, Week 48

change from baseline, improvement

Secondary/protocol endpoint

Mean Percent Change from Baseline in Fasting non-HDL Cholesterol

Time frame:Baseline, Week 48

percent change from baseline, improvement

Secondary/protocol endpoint

Mean Percent Change from Baseline in Fasting Triglycerides

Time frame:Baseline, Week 48

percent change from baseline, improvement

Patient-reported / QoL

1 endpoint

Secondary/protocol endpoint

Mean Change from Baseline in Short Form Version 2 (SF-36v2) Acute Form Domain Scores

Time frame:Baseline, Week 48

change from baseline, improvement

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateNovember 5, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the November 5, 2026 snapshot.